{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:04:31Z","timestamp":1768917871368,"version":"3.49.0"},"reference-count":36,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.5551\/jat.43414","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T18:25:21Z","timestamp":1530296721000},"page":"183-197","source":"Crossref","is-referenced-by-count":20,"title":["GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells"],"prefix":"10.5551","volume":"26","author":[{"given":"Hiroyuki","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nomiyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Terawaki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"},{"name":"Division of Cardiology, Department of Medicine, Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, UPMC and University of Pittsburgh School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Kawanami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makito","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Bruemmer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, UPMC and University of Pittsburgh School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Yanase","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Eng J Med 1998, 339: 229-234","DOI":"10.1056\/NEJM199807233390404"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Scheen AJ, Warzee F: Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care 2004, 27: 1840-1841","DOI":"10.2337\/diacare.27.7.1840"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Richard E. Pratley, Matthew Gilbert: Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud 2008, 5: 73-94","DOI":"10.1900\/RDS.2008.5.73"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pujadas G, Drucker DJ: Vascular biology of glucagon receptor superfamily peptide: Mechanistic and clinical relevance. Endocr Rev 2016, 37: 554-583","DOI":"10.1210\/er.2016-1078"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ding X, Saxena NK, Lin S, Gupta NA, Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonists, reverses hepatic steatosis in ob\/ob mice. Hepatology 2006, 43: 173-181","DOI":"10.1002\/hep.21006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG: An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A\u03b2 oligomers. J Clin Invest 2012, 122: 1339-1353","DOI":"10.1172\/JCI57256"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59: 1030-1037","DOI":"10.2337\/db09-1694"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa A, Kawamori R, Fujitani Y, Hirose T, Watada T: Exendin-4, a glucagonlike peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011, 405: 79-84","DOI":"10.1016\/j.bbrc.2010.12.131"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Hidetaka Morinaga, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T: Exendin-4, a glicagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. Diabetes 2014, 63: 3891-3905","DOI":"10.2337\/db13-1169"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tsutsumi Y, Nomiyama T, Kawanami T, Hamaguchi Y, Terawaki Y, Tanaka T, Murase K, Motonaga R, Tanabe M, Yanase T, Combined treatment with Exendin-4 and metformin attenuates prostate cancer growth. PLoS ONE 2015, 10: e0139709","DOI":"10.1371\/journal.pone.0139709"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol 2014, 13: 154","DOI":"10.1186\/s12933-014-0154-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kurakura K, Hamers AA, deWaard V, de Vries CJ. Nuclear receptors in atherosclerosis: a superfamily with many \u2018Good-fellas'. Mol Cell Endocrinol 2013, 368: 71-84","DOI":"10.1016\/j.mce.2012.05.014"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Cheang WS, Tian XY, Wong WT, Huang Y. The peroxisome proliferator-activated receptorors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol 2015, 172: 5512-5522","DOI":"10.1111\/bph.13029"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Lee SD, Tontonoz P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 2015, 242: 29-36","DOI":"10.1016\/j.atherosclerosis.2015.06.042"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol 2010, 30: 1535-1541","DOI":"10.1161\/ATVBAHA.109.191163"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ohkura N, Hijikuro M, Yamamoto A, Miki K: Molecular cloning of a novel thyroid\/steroid receptor superfamily gene from cultured rat neuronal cells. Biocem Biophys Res Commun 1994, 205: 1959-1965","DOI":"10.1006\/bbrc.1994.2900"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, Ohkura N, Kawamori R, Conneely OM, Bruemmer D: The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem 2006, 281: 33467-33476","DOI":"10.1074\/jbc.M603436200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nomiyama T, Zhao Y, Gizard F, Findeisen HM, Heywood EB, Jones KL, Conneely OM, Bruemmer D: Deficiency of the NR4A neuron-derived orphan receptor-1 attenuates neointima formation after vascular injury. Circulation 2009, 119: 577-586","DOI":"10.1161\/CIRCULATIONAHA.108.822056"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Gizard F, Zhao Y, Findeisen HM, Qing H, Cohn D, Heywood EB, Jones KL, Nomiyama T, Bruemmer D: Transcriptional regulation of S phase kinase-associated protein 2 by NR4A orphan nuclear receptor NOR1 in vascular smooth muscle cells. J Biol Chem 2011, 286: 35485-35493","DOI":"10.1074\/jbc.M111.295840"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T: Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011, 54: 2649-2659","DOI":"10.1007\/s00125-011-2241-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hirata Y, Kurobe H, Nishio C, Tanaka K, Fukuda D, Uematsu E, Nishimoto S, Soeki T, Harada N, Sakaue H, Kitagawa T, Shimabukuro M, Nakaya Y, Sata M: Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur J Pharmacol 2013, 699: 106-111","DOI":"10.1016\/j.ejphar.2012.11.057"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Bise JB; LEADER Steering Committee; LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016, 375: 311- 322","DOI":"10.1056\/NEJMoa1603827"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Petterson J, Visvoll T; SUSTAIN-6 Investigators: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016, 375: 1834-1844","DOI":"10.1056\/NEJMoa1607141"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Bruemmer D: C-peptide in insulinresistance and vascular complications: teaching an old dog new tricks. Circ Res 2006, 99: 1149-1151","DOI":"10.1161\/01.RES.0000251785.83860.3b"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Eriksson L, Saxelin R, Rohl S, Roy J, Caidahl K, Nystrom T, Hedin U, Razuvaev A: Glucagon-like peptide-1 receptor activation does not affect re-endothelialization bur reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of artery injury. J Vas Res 2015, 52: 41-52","DOI":"10.1159\/000381097"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27) Morales PE, Torres G, Sotomayor-Flores C, Pena-Oyarzun D, Pivera-Mejias P, Paredes F, Chiong M: GLP-1 Promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endoplastic reticulum-mitochondria cpoupling. Biochem Biophys Res Commun 2014, 446: 410-416","DOI":"10.1016\/j.bbrc.2014.03.004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28) Yang G, Lei Y, Inoue A, Piao L, Hu L, Jiang H, Sasaki T, Wu H, Xu W, Yu C, Zhao G, Ogasawara S, Okumura K, Kuzuya M, Cheng XW: Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress. Atherosclerosis 2017, 264: 1-10","DOI":"10.1016\/j.atherosclerosis.2017.07.014"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29) Piao L, Zhao G, Zhu E, Inoue A, Shibata R, Lei Y, Hu L, Yu C, Yang G, Wu H, Xu W, Okumura K, Ouchi N, Murohara T, Kuzuya M, Chen XW: Chronic phychological stress accerelates vascular senescence and impairs ischemia-induced neovascularization: the role of dipeptidyl peptidase-4\/glucagon-loke peptide-1-adiponectin axis. J Am Heart Assoc 2017, 6: e006421","DOI":"10.1161\/JAHA.117.006421"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30) Zhao Y, Nomiyama T, Findeinsen HM, Qing H, Aono J, Jones KL, Heywood EB, Bruemmer D: Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by histon acetylation. FEBS Lett 2014, 588: 4825-4830","DOI":"10.1016\/j.febslet.2014.11.017"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31) Li P, Liu Y, Yi B, Wang G, You X, Zhao X, Summer R, Qin Y, Sun J: MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGFBB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1. Crdiovasc Res 2013, 99: 185-193","DOI":"10.1093\/cvr\/cvt082"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32) Medunjanin S, Danisl JM, Weinert S, Dutzmann J, Burgbacher F, Brecht S, Bruemmer D, Kahne T, Naumann M, Sedding DG, Zuschratter W, Braun-Dullaeus RC: DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell proliferation through phosphorylation of the orphan nuclear receptor NOR1. Cardiovasc Res 2015, 106: 488-497","DOI":"10.1093\/cvr\/cvv126"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33) Meier JJ: GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8: 728-742","DOI":"10.1038\/nrendo.2012.140"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34) Ordelheide AM, Gerst F, Rothfuss O, Heni M, Haas C, Thielker I, Herzberg-Schafer S, Bohm A, Machicao F, Ullrich S, Stefan N, Fritsche A, Haring HU, Staiger H: Nor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion. Mol Metab 2013, 2: 243-255","DOI":"10.1016\/j.molmet.2013.06.003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35) Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygia Y, Buse JB, Chan JC, Choi J, Gustavson SM, Igbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hemandez AF; EXSCEL Study Group: Effect of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017, 377: 1228-1239","DOI":"10.1056\/NEJMoa1612917"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36) Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, Horikawa T, Yoshinaga Y, Yamashita S, Tanaka T, Terawaki Y, Tanaba M, Nabeshima K, Iwasaki A, Yanase T: Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation. Endocrinology 2017, 158: 4218-4232","DOI":"10.1210\/en.2017-00461"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37) Lim S, Kim KM, Nauck MA. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol Metab 2018, 29: 238-248","DOI":"10.1016\/j.tem.2018.01.011"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/2\/26_43414\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T01:40:13Z","timestamp":1571535613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/2\/26_43414\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.43414","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}